243 related articles for article (PubMed ID: 30301806)
1. Molecular mechanism of activation of the immunoregulatory amidase NAAA.
Gorelik A; Gebai A; Illes K; Piomelli D; Nagar B
Proc Natl Acad Sci U S A; 2018 Oct; 115(43):E10032-E10040. PubMed ID: 30301806
[TBL] [Abstract][Full Text] [Related]
2. Insights in the mechanism of action and inhibition of N-acylethanolamine acid amidase by means of computational methods.
Lodola A; Rivara S; Mor M
Adv Protein Chem Struct Biol; 2014; 96():219-34. PubMed ID: 25443959
[TBL] [Abstract][Full Text] [Related]
3. Advances in the discovery of N-acylethanolamine acid amidase inhibitors.
Bandiera T; Ponzano S; Piomelli D
Pharmacol Res; 2014 Aug; 86():11-7. PubMed ID: 24798679
[TBL] [Abstract][Full Text] [Related]
4.
Piomelli D; Scalvini L; Fotio Y; Lodola A; Spadoni G; Tarzia G; Mor M
J Med Chem; 2020 Jul; 63(14):7475-7490. PubMed ID: 32191459
[No Abstract] [Full Text] [Related]
5. Progress in the development of β-lactams as N-Acylethanolamine Acid Amidase (NAAA) inhibitors: Synthesis and SAR study of new, potent N-O-substituted derivatives.
Petracca R; Ponzano S; Bertozzi SM; Sasso O; Piomelli D; Bandiera T; Bertozzi F
Eur J Med Chem; 2017 Jan; 126():561-575. PubMed ID: 27915171
[TBL] [Abstract][Full Text] [Related]
6. N-acylethanolamine-hydrolyzing acid amidase and fatty acid amide hydrolase inhibition differentially affect N-acylethanolamine levels and macrophage activation.
Alhouayek M; Bottemanne P; Makriyannis A; Muccioli GG
Biochim Biophys Acta Mol Cell Biol Lipids; 2017 May; 1862(5):474-484. PubMed ID: 28065729
[TBL] [Abstract][Full Text] [Related]
7. Second-Generation Non-Covalent NAAA Inhibitors are Protective in a Model of Multiple Sclerosis.
Migliore M; Pontis S; Fuentes de Arriba AL; Realini N; Torrente E; Armirotti A; Romeo E; Di Martino S; Russo D; Pizzirani D; Summa M; Lanfranco M; Ottonello G; Busquet P; Jung KM; Garcia-Guzman M; Heim R; Scarpelli R; Piomelli D
Angew Chem Int Ed Engl; 2016 Sep; 55(37):11193-11197. PubMed ID: 27404798
[TBL] [Abstract][Full Text] [Related]
8. Anti-Inflammatory Effects of Fucoxanthinol in LPS-Induced RAW264.7 Cells through the NAAA-PEA Pathway.
Jin W; Yang L; Yi Z; Fang H; Chen W; Hong Z; Zhang Y; Zhang G; Li L
Mar Drugs; 2020 Apr; 18(4):. PubMed ID: 32326173
[TBL] [Abstract][Full Text] [Related]
9. Assay of NAAA Activity.
Tsuboi K; Ueda N
Methods Mol Biol; 2023; 2576():261-274. PubMed ID: 36152194
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of cyanamides as potent and selective N-acylethanolamine acid amidase inhibitors.
Malamas MS; Farah SI; Lamani M; Pelekoudas DN; Perry NT; Rajarshi G; Miyabe CY; Chandrashekhar H; West J; Pavlopoulos S; Makriyannis A
Bioorg Med Chem; 2020 Jan; 28(1):115195. PubMed ID: 31761726
[TBL] [Abstract][Full Text] [Related]
11. Different roles for the acyl chain and the amine leaving group in the substrate selectivity of
Ghidini A; Scalvini L; Palese F; Lodola A; Mor M; Piomelli D
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1411-1423. PubMed ID: 34256657
[No Abstract] [Full Text] [Related]
12. Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation.
Solorzano C; Zhu C; Battista N; Astarita G; Lodola A; Rivara S; Mor M; Russo R; Maccarrone M; Antonietti F; Duranti A; Tontini A; Cuzzocrea S; Tarzia G; Piomelli D
Proc Natl Acad Sci U S A; 2009 Dec; 106(49):20966-71. PubMed ID: 19926854
[TBL] [Abstract][Full Text] [Related]
13. Diacerein is a potent and selective inhibitor of palmitoylethanolamide inactivation with analgesic activity in a rat model of acute inflammatory pain.
Petrosino S; Ahmad A; Marcolongo G; Esposito E; Allarà M; Verde R; Cuzzocrea S; Di Marzo V
Pharmacol Res; 2015 Jan; 91():9-14. PubMed ID: 25447594
[TBL] [Abstract][Full Text] [Related]
14. Antinociceptive effects of the N-acylethanolamine acid amidase inhibitor ARN077 in rodent pain models.
Sasso O; Moreno-Sanz G; Martucci C; Realini N; Dionisi M; Mengatto L; Duranti A; Tarozzo G; Tarzia G; Mor M; Bertorelli R; Reggiani A; Piomelli D
Pain; 2013 Mar; 154(3):350-360. PubMed ID: 23218523
[TBL] [Abstract][Full Text] [Related]
15. N-Acylethanolamine-hydrolyzing acid amidase inhibition increases colon N-palmitoylethanolamine levels and counteracts murine colitis.
Alhouayek M; Bottemanne P; Subramanian KV; Lambert DM; Makriyannis A; Cani PD; Muccioli GG
FASEB J; 2015 Feb; 29(2):650-61. PubMed ID: 25384424
[TBL] [Abstract][Full Text] [Related]
16. N-acylethanolamine hydrolyzing acid amidase inhibition: tools and potential therapeutic opportunities.
Bottemanne P; Muccioli GG; Alhouayek M
Drug Discov Today; 2018 Aug; 23(8):1520-1529. PubMed ID: 29567427
[TBL] [Abstract][Full Text] [Related]
17. The N-acylethanolamine-hydrolyzing acid amidase (NAAA).
Tsuboi K; Takezaki N; Ueda N
Chem Biodivers; 2007 Aug; 4(8):1914-25. PubMed ID: 17712833
[TBL] [Abstract][Full Text] [Related]
18. NAAA inhibitor F96 attenuates BBB disruption and secondary injury after traumatic brain injury (TBI).
Li Y; Zhou P; Hu T; Ren J; Xu Y; Qiu Y; Lu C; Li Y
Eur J Pharmacol; 2021 Dec; 912():174561. PubMed ID: 34655598
[TBL] [Abstract][Full Text] [Related]
19. Potential analgesic effects of a novel N-acylethanolamine acid amidase inhibitor F96 through PPAR-α.
Yang L; Li L; Chen L; Li Y; Chen H; Li Y; Ji G; Lin D; Liu Z; Qiu Y
Sci Rep; 2015 Aug; 5():13565. PubMed ID: 26310614
[TBL] [Abstract][Full Text] [Related]
20. N-Acylethanolamine acid amidase (NAAA) inhibitor F215 as a novel therapeutic agent for osteoarthritis.
Zhou P; Xiang L; Yang Y; Wu Y; Hu T; Liu X; Lin F; Xiu Y; Wu K; Lu C; Ren J; Qiu Y; Li Y
Pharmacol Res; 2019 Jul; 145():104264. PubMed ID: 31063807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
